during the safety evaluation of several modified beta-lactam compounds ( carbapenems ) , hemolytic anemia and/or neutropenia were observed in rhesus monkeys , and anemia , neutropenia , and thrombocytopenia in rats , after approximately 2 weeks of intravenous administration .
C0282215
beta-lactam
C0006968
carbapenems